Stem Cell Applications and Good Manufacturing Practice (GMP) at the UC Davis Institute for Regenerative Cures
|
|
- Jonas McDaniel
- 6 years ago
- Views:
Transcription
1 Stem Cell Applications and Good Manufacturing Practice (GMP) at the UC Davis Institute for Regenerative Cures
2 UC Davis Stem Cell Program Disease Teams- 147 Basic, Translational, and Clinical Investigators working together Liver repair and regeneration, bioengineered livers Peripheral artery disease: revascularization to prevent amputation Eye degeneration/blindness Lung disease, lung repair and regeneration Skin: Non-healing ulcers, burn repair Bone repair, osteoporosis, cartilage regeneration Heart disease, infarction repair and stroke Neurodegenerative (Parkinsons, Huntingtons, Alzheimers, ALS) Neurodevelopmental disorders (Autism spectrum, FX-TAS, others) Kidney repair and regeneration Bioengineered bladders, tracheas, and other tissues and organs Blood disorders, autoimmune disorders (Scleroderma, MS) HIV treatment using gene-modified stem cells Hearing, inner ear cilia repair Tumor stem Cells, Cell-based immunotherapy for Cancer
3 How are stem cells defined?
4 How are stem cells defined? Mature Tissues 1) Self-renewal 2) Multi-potential 3) Highly proliferative Differentiation and Commitment
5 TYPES OF HUMAN STEM CELLS ADULT TYPE, MULTIPOTENT STEM CELLS, for instance: Hematopoietic Stem Cells - found in: Bone Marrow Umbilical Cord Blood Mobilized Peripheral Blood Can only make the tissue they are designated to make. There are also many other types of adult type stem cells PLURIPOTENT STEM CELLS Embryonic Stem Cells (or induced Pluripotent Stem Cells) Can make ALL tissues of the body, but not a complete organism TOTIPOTENT STEM CELLS Fertilized Oocytes Can make a complete organism.
6 Hematopoietic stem cell Hematopoietic stem cell Lineage committed progenitor cell
7 ADULT TYPE STEM CELLS Scanning electron microscope photograph
8 ADULT TYPE STEM CELLS Scanning electron microscope photograph HSC
9 ADULT TYPE STEM CELLS Scanning electron microscope photograph
10 Question we are most commonly asked: When will clinical trials using stem cells actually begin?
11 Answer: They BEGAN in First successful bone marrow transplantation from one human to another. Stem cells from the donor bone marrow were transplanted to regenerate the bloodforming system of a patient with leukemia.
12 LEUKEMIA TREATMENT USING ALLOGENEIC BONE MARROW STEM CELL TRANSPLANTATION healthy donor BONE MARROW TRANSPLANT patient with Leukemia recipient engrafts with donor cells - develops donor immune system MALE DONOR allogeneic transplant FEMALE RECIPIENT
13 LEUKEMIA TREATMENT USING ALLOGENEIC BONE MARROW STEM CELL TRANSPLANTATION healthy donor BONE MARROW TRANSPLANT patient with Leukemia recipient engrafts with donor cells - develops donor immune system MALE DONOR allogeneic transplant FEMALE RECIPIENT Anti-Cancer Effect 80% CURE RATE of Leukemia
14 LEUKEMIA TREATMENT USING ALLOGENEIC BONE MARROW STEM CELL TRANSPLANTATION healthy donor BONE MARROW TRANSPLANT patient with Leukemia SIDE EFFECT: anti-recipient reaction (GvHD) recipient engrafts with donor cells - develops donor immune system MALE DONOR allogeneic transplant FEMALE RECIPIENT Anti-Cancer Effect 80% CURE RATE of Leukemia
15 Hematopoietic stem cell therapies (expanded) Hematopoietic stem cells can be isolated using a cell surface marker such as CD34 and CD133 or by function of the enzyme Aldehyde Dehydroginase (ALDH). Hematopoietic stem cells have high ALDH expression. They can be infused I.V., in concentrated levels, much like a bone marrow transplant, to treat tissue damage. They find their own way from the bloodstream to the damaged tissue, especially to hypoxic areas and areas of inflammation, where they accumulate and initiate tissue repair.
16 Clinical trials currently ongoing Stem cells to treat blindness: Purified human hematopoietic stem cells. Title: A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes with Vision Loss from Retinopathy PI: Susanna S. Park, MD, PhD, Protocol # , UC Davis Department of Ophthalmology & Vision Science. Purpose: Investigate the feasibility and safety of intravitreal autologous bone marrow stem cell therapy in treating people with irreversible vision loss from retinal degenerative conditions or retinal vascular disorders. Fifteen subjects with vision loss will be injected intravitreally with autologous CD34 positive cells. Indication: Patients 18 years of age or older with 20/100 to Count Fingers visual acuity; vision loss due to dry age-related macular degeneration, retinitis pigmentosa, retinal vein occlusion, diabetic retinopathy, and hereditary maculopathy.
17 Restoring vision using the patient s own bone marrow CD34+ cells Hypothesis: Bone marrow stem cells have regenerative capacity. They can promote blood vessel growth. They may rescue photoreceptors by improving blood flow. The patient s own bone marrow CD34+ cells are safe (no rejection, no tumor formation).
18 Restoring vision using the patient s own bone marrow CD34+ cells In vitro and in vivo experiments were carried out to confirm the hypothesis. An Investigational New Drug (IND) application was submitted to the US Food and Drug Administration (FDA). A Phase I clinical study, a SAFETY STUDY with secondary endpoint of EFFICACY was approved by the FDA and initiated by UC Davis.
19 Restoring vision using the patient s own bone marrow CD34+ cells Outpatient procedure in hospital Bone marrow aspirate Patient exam Cell injection GMP grade magnetic cell isolation Transport to treatment area Release tests / QC-QA
20 Restoring vision using the patient s own bone marrow CD34+ cells Outpatient procedure in hospital Bone marrow aspirate Patient exam Cell injection Start at 8 AM finish at 5 PM GMP grade magnetic cell isolation Transport to treatment area Release tests / QC-QA
21 Study Outcome
22 Study Outcome A: Fundus photograph prior to treatment B: Fundus photograph 3 months after treatment C: Fluorescent angiogram prior to treatment D: Fluorescent angiogram 3 months after treatment SUBJECT 1
23 Retinal hemorrhage Study Outcome A: Fundus photograph prior to treatment B: Fundus photograph 3 months after treatment C: Fluorescent angiogram prior to treatment D: Fluorescent angiogram 3 months after treatment SUBJECT 1
24 Study Outcome Microaneurysms Retinal ischemia A: Fundus photograph prior to treatment B: Fundus photograph 3 months after treatment C: Fluorescent angiogram prior to treatment D: Fluorescent angiogram 3 months after treatment SUBJECT 1
25 Intravitreal Autologous Bone Marrow CD34+ Cell Therapy for Ischemic and Degenerative Retinal Disorders: Preliminary Phase 1 Clinical Trial Findings Susanna S. Park, Gerhard Bauer, Mehrdad Abedi, Suzanne Pontow, Athanasios Panorgias, Ravi Jonnal, Robert J. Zawadzki, John S. Werner, and Jan Nolta IOVS January :81
26 Mesenchymal Stem Cells Mesenchymal stem cells have the potential to form bone, cartilage, tendon, fibroblast, fat, and muscle, and may have other very exciting potentials such as contributing to the repair of damaged heart and skeletal muscle, liver, pancreas, kidney, spinal cord, and even brain. Dr. Jan Nolta, since the late 1980s, has pioneered MSC research, and has characterized the in vitro and in vivo characteristics of MSCs. MSCs home into multiple tissues in immune deficient mice, including brain (Meyerrose at al, Stem Cells 2007). Therefore, we may be able to deliver them intravenously to contribute to tissue repair. The possibility of repairing tissues from easily harvested and unwanted fat cells holds broad appeal, and is an intriguing possibility that could have dramatic effect on health care.
27 In models of acute local injury, MSC preferentially home to, or accumulate in, the damaged tissue (Wu, Nolta et al, Transplantation 2003). Dr. Nolta s lab has been studying these processes for human stem cells in immune deficient mouse models and at the molecular level.
28 Iron nanoparticle-loaded human stem cells are rapidly recruited to a site of ischemic injury Tail vein injection of 5x10 5 human marrow stem cells at T = 0 hours Non-ischemic Limb - 12 hours Ischemic Limb - 12 hours Ischemic Limb - 48 hours Capoccia et al., 2009
29 Clinical Trials in Development Stem cells in peripheral vascular disease: Save limbs from amputation planned clinical trial with John Laird using mesenchymal stem cells Damaged limb- no blood flow Blood flow restored by Stem Cell Infusion
30 Working toward a clinical trial for CLI following dialog with FDA, IND submission and approval MSC from healthy donors will be gene modified to secrete VEGF, and will be injected into limbs of patients with severe ischemia. Goal: Prevention of amputation. Evaluation of revascularization: Imaging of blood flow and new vessel growth in the affected limb. FDA Pre-pre IND meeting successful, pre IND package assembled and to be submitted. In vivo studies ongoing to assure safetey and efficacy. Clinical trial IND to be submitted 2015, with clinical trial starting after IND approval.
31 Completed Stem Cell Clinical Trial Jeffrey Southard, MD I.V. Infusion of ALLOGENEIC MSCs to repair damage from heart attack (placebo controlled). Besides tissue repair effects, MSCs have potent immuno-modulatory effects: MSCs do not express MHC Class II molecules (no HLA antigens), and are sheltered from an immune response. Therefore, cellular therapies with allogeneic MSCs are possible. Trial has been completed at UC Davis. MSCs (=Prochymal) provided by Osiris. 5 Patients treated. at UC Davis
32 The role of MSC in the treatment of Huntington s disease: Translation from pre-clinical to clinical applications Developed by Dr. Jan A. Nolta Professor, Director of the Stem Cell Program and Institute for Regenerative Cures, University of California, Davis Neuron generated in vitro Photo courtesy of Paul Knoepfler, UC Davis Stem Cell Program / Shriners Hospital
33 Huntington's Disease (HD) is a fatal, dominant neurogenetic disorder resulting from a variable length polyglutamine (polyq) repeat CAG expansion in exon 1of the HD gene. Repeats confer a toxic gain of function on the protein huntingtin (htt). Currently, no preventative or curative treatments exist for HD. Half of the children born to a parent with HD will be affected. Genetic testing of young people living at risk is very controversial, since there is currently no cure. In addition to new drugs being developed to treat different aspects of the disease such as chorea, cellular therapy and gene therapy provide the best options for permanent cures.
34 Mesenchymal Stem Cells (MSC): Reparative adult stem cells that can act as excellent delivery vehicles in the body Bone Marrow is harvested From a normal, healthy donor Cells expanded in a clean room facility
35 Nolta lab: Development of models to study biosafety and efficacy of engineered human Marrow Stromal Cells / Mesenchymal Stem Cells (MSC) Decade-long biosafety studies: Bauer et al., Nolta lab Mol Ther 16, 1308 (2008)
36 Studies Underway, Working Toward Cellular Therapy Trials for Huntington s disease 1. MSC to test neurorestorative effects. 2. MSC to continually secrete Brain Derived Neurotrophic Factor (BDNF) to slow down degeneration of neurons
37 WHY plan to use Mesenchymal stem cells?? Strong safety profile Neurorestorative effects Relative ease of isolation and expansion
38 Neurorestorative effects of MSC Reduce inflammation Increase vascularization Reduce death of damaged neurons Restore synaptic connections between damaged neurons MSC can be safely delivered into the brain and spinal cord, in small and large animal models (Parr et al, 2007, Pittenger 2008, and Joyce et al, 2010)
39 Following intravenous injection, only low levels of human MSC cross the blood brain barrier in chronic disease models (Meyerrose et al 2007). To effectively combat most neurodegenerative diseases we will need to deliver larger numbers of MSC directly into the brain tissue. We are validating the biosafety of catheter-based MSC delivery systems into the brains of rodents and non-human primates.
40 Brain: the final frontier MSC use the external surface of the vasculature as train tracks to migrate throughout the brain tissue to deliver factors to damaged neurons
41 Medium Spiny Neuron Damaged/Lost in HD- they control movement, cognition and emotion Kelly, Dunnet and Rosser, Biochem. Soc. Trans. (2009) 37,
42 Damaged neurons can round up and retract axons: this prevents effective signaling from cell to cell in the neural network
43 Mesenchymal stem cells can restore synaptic connections between neurons by secreting factors (reviewed in Regenerative Medicine, Joyce et al, Nolta lab, 2010)
44 MSC migrate to damaged striatum after implantation into the brain in an HD rat model Sadan et al, 2009 MSC (dark spots, white arrows) migrated from injection site at the red arrow to the area of striatal damage (white lesion)
45 Our ongoing studies show that human MSC, injected directly into the brains of immune deficient mice, survive for months and migrate readily throughout the neural tissue. MSC are still present in robust numbers and the brain tissue architecture is unaltered.
46 We performed biosafety testing of Intracranial MSC implantation in Non-human primates MSC expanded under GMP conditions were transplanted into the brains of 3 fetal primates under ultrasound guidance Brains and other organs were collected at term- 5 months later
47 Intra-ventricular MSC transfer in fetal non-human primates. Sonogram in left panel shows route of transfer (arrow) through the coronal suture. MSC were injected at 70 days gestation; (early second trimester) during maximal neuronal proliferation and prior to development of the immune system. (Tarantal Lab, California National Primate Center, UC Davis)
48 Intracranial injection of human mesenchymal stem cells into fetal non-human primate brain- the most stringent biosafety model available: 1. After 5 months, human mesenchymal stem cells were still present in the brain tissue. 2. No tumors or other tissue abnormalities were detected. 3. Continued studies of MSC therapy for HD were warranted. 4. CIRM Disease Team grant application followed.
49 Working toward a clinical trial for HD following dialog with FDA, IND submission and approval MSC from healthy donors will be gene modified to secrete BDNF, and will implanted near the affected portion of the brain in symptomatic HD patients. Evaluation of neuroprotective effects: slowing of disease progression as measured by Total Functional Capacity score and delay in volumetric MRI changes known to occur in HD. Clinical improvement in severity of movement disorders and cognitive impairment as measured by the Unified HD Rating Scale (UHDRS) and a battery of cognitive tests. FDA Pre-pre IND meeting successful, pre IND package assembled and to be submitted. In vivo studies ongoing to assure safetey and efficacy. Clinical trial IND to be submitted 2015, with clinical trial starting after IND approval.
50 Skin Repair using Mesenchymal Stem Cells (MSCs) and induced Pluripotent Stem Cells (ipscs) MSC for Non-Healing Ulcers: Biological Band Aids (Isseroff/Nolta/Fierro with German partners- Technical University of Munich). MSC for Severe Burns: Palmieri, Greenhalgh - Shriners Hospital. ipsc for Epidermolysis Bullosa (EB): Growing NEW, gene corrected, intact skin for children with EB. CIRM disease team - Bauer with Stanford.
51 TYPES OF HUMAN STEM CELLS Hematopoietic Stem Cells found in Bone Marrow Umbilical Cord Blood Mobilized Peripheral Blood = ADULT TYPE, MULTIPOTENT STEM CELLS can only make the tissue they are designated to make Embryonic Stem Cells (or induced Pluripotent Stem Cells) = PLURIPOTENT STEM CELLS can make ALL tissues of the body, but not a complete organism Fertilized Oocytes = TOTIPOTENT STEM CELLS can make a complete organism.
52 Induced PLURIPOTENT STEM CELLS These stem cells are generated from a skin cell or other mature cell of a patient. They resemble almost completely naturally occuring embryonic stem cells. Can be generated entirely in the lab. Do not need any cells from an embryo. Can be differentiated into all tissues of the body. Most importantly: Can generate a patient s own tissue (no tissue rejection).
53 Skin fibroblasts GENERATION of induced Pluripotent Stem Cells (ipscs) Transduction with 4 genes using gene therapy vectors Culture of pluripotent stem cells Differentiation into mature tissues
54 Liver Bioengineering Team- Decellularized liver matrix Zhou and Wu, Nolta and Zern labs 2010
55 Developing Cell and Organ Replacement for Individual Patients Skin fibroblastsfrom the patient Induced pluripotent stem cells Patient-specific human Hepatocytes in culture Transplant Into patient Place on scaffold
56 HEART MUSCLE CELLS DERIVED FROM PLURIPOTENT STEM CELLS Single cells beating Cell sheet synchronized beating
57 With pluripotent stem cells, can we make functional neurons? When a part of a rat s spinal cord gets cut out, the rat, like a human with a similar injury, will not be able to walk or move the legs. When neuronal stem cells derived from pluripotent stem cells are inserted into the spinal cord injury site, these stem cells differentiate into functional nerve cells that connect to the ends of the severed spinal cord and make the paralyzed rats walk again.
58 Pluripotent stem cell derived neurons can repair a massive injury in the spinal cord Fluorescent double immunolabeling after in vivo grafting reveals that C17.2 NT- 3 NSCs (GFP label, green channel) completely fill C3 wire knife lesion cavity (outlined by GFAP immunolabeling, red channel) and migrate for short distances from the graft site in rostral and caudal directions. Lu P, Jones LL, Snyder EY, Tuszynski MH. Department of Neurosciences, University of California at San Diego, La Jolla , USA. Exp Neurol Jun;181(2):
59 Rats with spinal cord defect 5 days after stem cell transplant Douglas Kerr et al., Johns Hopkins School of Medicine, Journal of Neuroscience, 2003
60 Rats with spinal cord defect 120 days after stem cell transplant Douglas Kerr et al., Johns Hopkins School of Medicine, Journal of Neuroscience, 2003
Des cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationThe New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017
The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,
More informationAt the conclusion of this lesson you should be able to:
Learning Objectives At the conclusion of this lesson you should be able to: Understand the key terms and definitions regarding stem cells Differentiate between the adult and embryonic stem cells Differentiate
More informationNPTEL Biotechnology Tissue Engineering. Stem cells
Stem cells S. Swaminathan Director Centre for Nanotechnology & Advanced Biomaterials School of Chemical & Biotechnology SASTRA University Thanjavur 613 401 Tamil Nadu Joint Initiative of IITs and IISc
More informationWhat Are Stem Cells? Where Are These Stem Cells?
While stem cell therapies may seem to have appeared overnight, they have been practiced for some time prior to the recent burst in new applications and stem cell sources. The most recent developments in
More informationRegenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016
Regenerative Medicine Halland Chen, MD Speaker Disclosures I disclose that I am not a consultant or have any financial interests. 2 What is regenerative medicine? Regeneration of human cells, tissues,
More informationANAT 3231 Cell Biology Lecture 21 Stem Cells
ANAT 3231 Cell Biology Lecture 21 Stem Cells Outline What are Stem Cells? Totipotency - Pluripotency - Multipotency What are different sources of Stem Cells? Embryonic vs Adult Pros and Cons for each type
More informationANAT 2341 Embryology Lecture 18 Stem Cells
ANAT 2341 Embryology Lecture 18 Stem Cells 29 September 2010 Dr Antonio Lee Neuromuscular & Regenera
More informationClip 1: Hip dysplasia Clip 2: Vet-Stem s Dr. Harman
Stem Cells Many breeds of large dogs are affected by hip dysplasia. This degenerative disease affects their hind legs, hindering mobility. Watch as scientists at Vet-Stem explain how stem cells are used
More informationCharacteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal)
STEM CELLS (p 2-8) Overview The body is made up of about 200 different kinds of specialised cells, such as muscle cells, nerve cells, fat cells and skin cells. Cells with the capacity to give rise to the
More informationStem Cells: A Primer National Institutes of Health
Stem Cells: A Primer National Institutes of Health I. INTRODUCTION Research on stem cells is advancing knowledge about how an organism develops from a single cell and how healthy cells replace damaged
More informationFrom Stem Cell to Any Cell
sciencenewsforkids.org http://www.sciencenewsforkids.org/2005/10/from-stem-cell-to-any-cell-2/ From Stem Cell to Any Cell By Emily Sohn / October 11, 2005 For maybe a day, about 9 months before you were
More informationBackground. Background. Background. Background. Background 3/4/2013
3/4/213 Human Very Small Embryonic-like Stem Cells (s) Capacity to Regenerate Bone Tissue: A Potential Cell-based Therapy for Autogenous Bone Grafting Aaron M. Havens, DMD Need to discover an improved
More informationShould Embryonic Stem Cell Research be Permitted to Continue? Over the past few years a debate has been going on over the moral implications of
Courtesy of Christopher Waits. Used with permission. Waits 1 Should Embryonic Stem Cell Research be Permitted to Continue? Over the past few years a debate has been going on over the moral implications
More informationNEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:
NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY: Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient s
More informationFundamental properties of Stem Cells
Stem cells Learning Goals: Define what a stem cell is and describe its general properties, using hematopoietic stem cells as an example. Describe to a non-scientist the current progress of human stem cell
More informationOutcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL
Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo
More informationThe Role of Adult Stem Cells in Personalized and Regenerative Medicine
The Role of Adult Stem Cells in Personalized and Regenerative Medicine Christopher J. Neill, Director of Corporate Operations American CryoStem Corporation Objective To illustrate the potential benefits
More informationStem Cells Canadian Perspective
Stem Cells Canadian Perspective John Laffey Critical Illness and Injury Research Centre, Keenan Research Centre, St Michael s Hospital. Departments of Anesthesia, Physiology and Interdepartmental Division
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
More informationStem Cells for the Future Treatment of Parkinson's Disease
Home Stem Cell Basics Stem Cell Basics I. Introduction II. III. IV. What are the unique properties of all stem cells? What are embryonic stem cells? What are adult stem cells? V. What are the similarities
More informationUNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE
Massachusetts Institute of Technology Harvard Medical School Brigham and Women s Hospital VA Boston Healthcare System 2.79J/3.96J/20.441/HST522J UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE
More informationSTEM CELLS IN NEUROLOGY ISABELLE COCHRANE MERIT
STEM CELLS IN NEUROLOGY BY ISABELLE COCHRANE MERIT RESEARCH PAPER BASED ON PATHOLOGY LECTURES AT MEDLINK 2011 1 Abstract Ever since their discovery, stem cells have been heralded as the ultimate cure to
More informationStem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean?
STO-120 Stem Cells Part 1: What is a Stem Cell? Stem cells differ from other kinds of cells in the body. When a stem cell divides by mitosis, each new cell has the potential to either remain a stem cell
More informationPACT. PACT Program. Production Assistance for Cellular Therapies
PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert
More information5.5. Multicellular Life. Multicellular organisms depend on interactions among different cell types.
5.5 Multiular Life VOCABULARY tissue organ organ system differentiation stem 5b, 5c, 5B examine specialized s, including roots, stems, and leaves of plants; and animal s such as blood, muscle, and epithelium;
More informationInVivo Therapeutics. Developing Innovative Products for Spinal Cord Injury
1 Developing Innovative Products for Spinal Cord Injury 2 Forward-Looking Statements Before we begin, we would like to remind everyone that during our presentation, we will be making forward-looking statements
More information5.5. Multicellular Life. Multicellular organisms depend on interactions among different cell types.
5.5 Multicellular Life VOCABULARY tissue organ organ system cell differentiation stem cell Key Concept Cells work together to carry out complex functions. MAIN IDEAS Multicellular organisms depend on interactions
More informationRecent Progress in ips Cell Research and Application
Recent Progress in ips Cell Research and Application Shinya Yamanaka, M.D., Ph.D. Center for ips Cell Research and Application (CiRA), Kyoto University, Japan Takeda - CiRA Joint Program, Shonan, Japan
More informationTissue Engineering and the Brain. Susan Perry Bioengineering Program Lehigh University
Tissue Engineering and the Brain Susan Perry Bioengineering Program Lehigh University ...all the most acute, most powerful, and most deadly diseases, and those which are most difficult to be understood
More informationStem Cells: Ethics and Oversight May 24, Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center
Stem Cells: Ethics and Oversight May 24, 2017 Sidney H. Golub, Ph.D. Interim Director Sue & Bill Gross Stem Cell Research Center Nobel Laureates 2012 John Gurdon Shinya Yamanaka Pluripotent Stem Cell PLURIPOTENT
More informationImmunogenicity of Stem Cells in Therapeutic Applications. MDPB-Registry meeting nov 25th Stem cell immunogenicity in therapeutic applications
Immunogenicity of Stem Cells in Therapeutic Applications MDPB-Registry meeting nov 25th 2016 Stem cell immunogenicity in therapeutic applications Has it been underestimated? Transplantation of any type
More informationEMBRYONIC STEM CELL RESEARCH: ALTERNATIVE METHODS & ALZHEIMER S DISEASE
EMBRYONIC STEM CELL RESEARCH: ALTERNATIVE METHODS & ALZHEIMER S DISEASE BY KHYATI PATEL Word count: Approx 2300 Grade awarded June 2006: PASS WITH DISTINCTION RESEARCH PAPER BASED ON PATHOLOGY LECTURES
More informationPRIME-XV Cell Therapy Products by
PRIME-XV Cell Therapy Products by Product List 2017 TRINOVA BIOCHEM now distributes the PRIME-XV Cell Therapy line by Irvine Scientific in Germany, Austria and Switzerland. Irvine Scientific is a worldwide
More informationBIOTECHNOLOGY. Unit 8
BIOTECHNOLOGY Unit 8 PART 1 BASIC/FUNDAMENTAL SCIENCE VS. APPLIED SCIENCE! Basic/Fundamental Science the development and establishment of information to aid our understanding of the world.! Applied Science
More informationSTEM CELLS. An Interactive Qualifying Project Report. Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE
IQP-43-DSA-2135 IQP-43-DSA-8130 STEM CELLS An Interactive Qualifying Project Report Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE In partial fulfillment of the requirements for the Degree
More informationPRIME-XV Cell Therapy Products by
PRIME-XV Cell Therapy Products by Product List 2017 TRINOVA BIOCHEM now distributes the PRIME-XV Cell Therapy line by Irvine Scientific in Germany, Austria and Switzerland. Irvine Scientific is a worldwide
More information4006: Cellular Therapy Infusion
4006: Cellular Therapy Infusion Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: / / CIBMTR Form 4006 revision 1 (page 1 of 9). Last Updated July, 2016. If
More informationDepartment of Clinical Application, Cebter for ips cell Research and Application, 53 Kawahara-cho Shogoin Sakyo-ku, Kyoto,
Department of Clinical Application, Cebter for ips cell Research and Application, Kyoto University 53 Kawahara-cho Shogoin Sakyo-ku, Kyoto, 606-8507 JAPAN Phone: 81-75-366-7066, Fax: 81-75-366-7071 Daisuke
More informationEmbryonic development, epigenics and somatic cell nuclear transfer - The science and its social implications -
Embryonic development, epigenics and somatic cell nuclear transfer - The science and its social implications - Moshe Yaniv Unité d Expression Génétique et Maladies, Institut Pasteur, Paris, France September
More informationHCT/P Regulation vs 361 Products
HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public
More informationSTEM CELLS BONE FRACTURE
BIOLOGY UNIT 2 MRS. CATHERINE JACKSON STEM CELLS BONE FRACTURE By AYESHA SYED 10C 2 Stem Cell (Introduction) Stem cells are undifferentiated cells that have not yet become a specialised cell, with a specific
More informationStem Cell Principle -
Effective Date: 31.10.2017 Doc ID: 20290214 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Stem Cell Principle - Rationale Research on human stem cells and their
More informationAdult Stem Cells by David A. Prentice, Ph.D.
Adult Stem Cells by David A. Prentice, Ph.D. Within just a few years, the possibility that the human body contains cells that can repair and regenerate damaged and diseased tissue has gone from an unlikely
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationPhysicsAndMathsTutor.com. Question Number. Answer Additional guidance Mark. 1(a) 1. reference to stem cells being {totipotent / pluripotent} ;
1(a) 1. reference to stem cells being {totipotent / pluripotent} ; 2. can specialise or differentiate / can give rise to {differentiated / specialised} cells ; 3. idea that these can replace damaged cells
More informationJohn Gurdon was testing the hypothesis of genomic equivalence or that when cells divide they retain a full genomic compliment.
1. (15 pts) John Gurdon won the 2012 Nobel Prize in Physiology or Medicine for work he did in the 1960 s. What was the major developmental hypothesis he set out to test? What techniques did he development
More informationNASDAQ: ABEO
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933,
More informationCellular Therapies for Skin Disease
Cellular Therapies for Skin Disease A NTHONY ORO MD/ PHD ORO@ STANFORD. EDU A SSOC D IRECTOR C ENTER FOR D EFINITIVE AND C URATIVE M EDICINE P ROGRAM IN E PITHELIAL B IOLOGY Many cell lineages compose
More informationTHE PROMISE OF STEM CELLS. UCLA Health David Geffen School of Medicine
UCLA Health David Geffen School of Medicine SUMMER 2013 THE PROMISE OF STEM CELLS Stem-cell research is on the cusp of transforming patient care through the development of personalized therapies for a
More informationGenetic Basis of Development & Biotechnologies
Genetic Basis of Development & Biotechnologies 1. Steps of embryonic development: cell division, morphogenesis, differentiation Totipotency and pluripotency 2. Plant cloning 3. Animal cloning Reproductive
More informationScientists have successfully used stem cells to reverse this paralysis. Magnification 0.02
1 The photograph below shows an X-ray of a dachshund. The dachshund is a breed of dog that is at higher risk of paralysis due to spinal injury. Scientists have successfully used stem cells to reverse this
More informationBlue Marble University Biology Course Handbook
Blue Marble University Biology Course Handbook A Summary of Course Descriptions Courses and Content Subject to Change Without Notice BlueMarbleUniversity.com Info@bluemarbleuniversity.com Stem Cell Biology
More informationA novel stem cell for auditory neuron regeneration.
A novel stem cell for auditory neuron regeneration. M.A.Huisman*, R. el Seady*, C.F.H.M.Löwik # en J.H.M.Frijns* Departments of Ear, Nose & Throat* and Molecular Imaging #, Leiden University Medical Centre,
More informationThe 3Rs: are Human Stem Cells and Organs on Chip alternatives?
The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human
More informationLong-Term Follow-Up in Gene Transfer Clinical Research
Long-Term Follow-Up in Gene Transfer Clinical Research Jan P. Vleck, MD CIP Institutional Biosafety Committee Services A Division of WIRB www.ibcservicepoint.com ibcs@wirb.com What is LTFU? the collection
More informationCell Processing at CAGT. Overview. Adrian P. Gee Center for Cell & Gene Therapy. CAGT Introduction
Cell Processing at CAGT Adrian P. Center for Cell & Gene Therapy CAGT Introduction Overview Facility Description Products prepared Flow cytometry Quality Control Quality Assurance 1 Center for Cell & Gene
More informationSpecial Report. medicine? Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D.
The new england journal of medicine Special Report Balancing Safety and Innovation for Cell-Based Regenerative Medicine Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D. Regenerative medicine is a field
More informationQ4 and Full Year 2017 Conference Call. February 22, 2018
Q4 and Full Year 2017 Conference Call February 22, 2018 Agenda Welcome McDavid Stilwell VP, Corporate Communications and Investor Relations Q4 2017 and Full Year Review and Recent Highlights Dr. Sandy
More informationProduction Assistance for Cellular Therapies PACT
Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)
More informationStem Cells and Regenerative Medicine
Q 0 Stem Cells and Regenerative Medicine Technologies and capabilities to add value to your company Differentiation HA-PPS for cartilage Parallel culture optimisation Stem Cell Therapies Fetal EPCs and
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationYOUR OWN LIFE
YOUR OWN LIFE Stromal Tissue (ST), a Regenerative Source There is a worldwide consensus that the isolation and collection of regenerative Mesenchymal Stem Cells (MSC s) from differentiated body tissues
More informationDevelopment of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach
3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the
More informationFREQUENTLY ASKED QUESTIONSON STEM CELLS AND THEIR CLINICAL APPLICATIONS/THERAPY
FREQUENTLY ASKED QUESTIONSON STEM CELLS AND THEIR CLINICAL APPLICATIONS/THERAPY Basics of Stem Cells 1) What is a cell? Cell is the building block of our body. It is the smallest structural and functional
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationPotential new therapies for HD
Potential new therapies for HD 2016 HDSA Northern California Annual Convention Vicki Wheelock MD Director, HDSA Center of Excellence at UC Davis Saturday May 21, 2016 Sacramento CA The quest for disease
More informationSTEM CELLS. An Interactive Qualifying Project Report. Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE
IQP-43-DSA-2840 IQP-43-DSA-7251 STEM CELLS An Interactive Qualifying Project Report Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE In partial fulfillment of the requirements for the Degree
More informationFujifilm s Initiatives in Regenerative Medicine
Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business
More informationAdipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords
Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords Dr. Vasiliki E Kalodimou, Head of Flow Cytometry-Research and Regenerative Medicine Department, IASO-Maternity
More informationDB3230 Midterm 1 11/15/2013 Name:
1. (15 pts) Nuclear cloning by John Gurdon was rarely successful in producing fertile adults. Why not? Explain why serial transplantation improves the success rate. What else could you do to improve the
More informationClinical Applications of Mesenchymal Stromal Cells
Clinical Applications of Mesenchymal Stromal Cells John Girdlestone PhD Stem Cells and Immunotherapies NHS Blood and Transplant, Oxford John Radcliffe Hospital Mesenchymal Stromal Cells (MSC) Fibroblastic,
More informationAuthor Proof. Review. Mesenchymal stem cells for the treatment of neurodegenerative disease
Review Mesenchymal stem cells for the treatment of neurodegenerative disease Mesenchymal stem cells/marrow stromal cells (MSCs) present a promising tool for cell therapy, and are currently being tested
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders March 2018 Mar-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationStem Cell Services. Driving Innovation for Stem Cell Researchers
Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,
More informationStem cells in regenerative medicine: introduction
Published Online May 11, 2011 Stem cells in regenerative medicine: introduction Dusko Ilic 1, and Julia M. Polak 2* 1 Kings College London School of Medicine, Division of Women s Health, Assisted Conception
More informationCloning. 1. What is cloning: Natural and artificial 2. Cloning of what? 3. Embryonic development of multi-cellular organisms:
Cloning 1. What is cloning: Natural and artificial 2. Cloning of what? 3. Embryonic development of multi-cellular organisms: cell division, morphogenesis, differentiation 2. Plant cloning 3. Animal cloning
More informationThe Future of Health Research: It s in Our Culture
The Future of Health Research: It s in Our Culture Pop quiz. Who was the inventor of the light bulb? Thomas Edison (1847-1931) If you answered Thomas Alva Edison, you re absolutely wrong. But don t feel
More informationRegeneration of spinal cord injury (SCI) : What we know so far. By: Kendra Michaud
Regeneration of spinal cord injury (SCI) : What we know so far By: Kendra Michaud INTRODUCTION BACKGROUND/IMPACT Neerumalla, Dr. Ravali. Spinal Cord Injury - Causes, Symptoms, Diagnosis, Treatment & Prevention.
More informationFDA Oversight of Gene Therapy
FDA Oversight of Gene Therapy Celia M. Witten, Ph.D., M.D. Deputy Director, FDA CBER Rare Disease and Orphan Products Breakthrough Summit NORD October 17, 2016 Hyatt Regency Crystal City Crystal City,
More informationHistory and Recent Advances of Stem Cell Biology and the Implications for Human Health
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2015 History and Recent Advances of Stem Cell Biology and the Implications for Human
More informationSUPPLEMENTARY INFORMATION
a before amputation regeneration regenerated limb DERMIS SKELETON MUSCLE SCHWANN CELLS EPIDERMIS DERMIS SKELETON MUSCLE SCHWANN CELLS EPIDERMIS developmental origin: lateral plate mesoderm presomitic mesoderm
More informationRelative cost of hepatocytes
Relative cost of hepatocytes - WORKPACKAGE 8 PROGENITOR CELLS FOR BIO- ARTIFICIAL LIVER UNEW, Charité, SCS StemCellSystems WP2 System design and medical device regulatory requirements WP7 Communications,
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationThe promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education
The promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education Academies Cell Therapy Workshop Washington, October 13, 2016 Michel
More informationOverview: Unmet Need: 1 Cell Sense: Enabling in vivo cell tracking
1 Cell Sense: Enabling in vivo cell tracking Overview: A challenge in the development and translation of new cellular therapies is effective tracking of cells post-transfer in both animal and human subjects.
More information#SIS25th. 25th Annual Meeting Slides
25th Annual Meeting Slides Stem Cell for Spine Care - From dish to disc Wenchun Qu, MD, PhD Mayo Clinic Rochester Disclosures ØConsultant, DePuy Synthes ØBoard of Directors, American Academy of Regenerative
More informationChapter 8 Cell Diversity
Chapter 8 Cell Diversity Mr. C. Biology 1 Future? Chapter 8 Cell Diversity Cells, Tissues, Organs and Systems Cells have different shapes because they have different jobs to do. A nerve cell is very different
More informationRegulatory Updates on Cellular Therapy Products in Japan
Regulatory Updates on Cellular Therapy Products in Japan Daiju Okuda, Ph.D. Principle Reviewer Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA), Japan September
More information